Patents by Inventor Peter Wisdom Atadja

Peter Wisdom Atadja has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20180289670
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: June 12, 2018
    Publication date: October 11, 2018
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20180071251
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 15, 2018
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20170246147
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: May 17, 2017
    Publication date: August 31, 2017
    Applicant: Novartis AG
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20170027909
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 2, 2017
    Applicant: Novartis AG
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS
    Publication number: 20160199350
    Abstract: The invention relates to a combination which comprises: (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases.
    Type: Application
    Filed: November 30, 2015
    Publication date: July 14, 2016
    Inventors: Peter Wisdom Atadja, Ricky Wayne Johnstone, Henry Miles Prince, Mark John Bishton, Simon James Harrison
  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20150094274
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS
    Publication number: 20130171141
    Abstract: The invention relates to a combination which comprises: (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases.
    Type: Application
    Filed: August 31, 2011
    Publication date: July 4, 2013
    Applicant: NOVARTIS AG
    Inventors: Peter Wisdom Atadja, Ricky Wayne Johnstone, Henry Miles Prince, Mark John Brishton, Simon James Harrison
  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20130029927
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: July 25, 2012
    Publication date: January 31, 2013
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF BONE DESTRUCTION
    Publication number: 20120029047
    Abstract: The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis.
    Type: Application
    Filed: August 2, 2011
    Publication date: February 2, 2012
    Inventors: Peter Wisdom Atadja, Joseph Daniel Growney, Wenlin Shao
  • Combination of an HDAC inhibitor and an antimetabolite
    Patent number: 8093220
    Abstract: The invention relates to a combination which comprises: (a) a HDAI; and (b) an anti-metabolite, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: January 10, 2012
    Assignee: Novartis AG
    Inventor: Peter Wisdom Atadja
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA
    Publication number: 20110288144
    Abstract: The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 26, 2011
    Publication date: November 24, 2011
    Applicant: NOVARTIS AG
    Inventor: Peter Wisdom Atadja
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS
    Publication number: 20110124701
    Abstract: The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of lymphoproliferative diseases, in particular, cutaneous T-cell lymphomas.
    Type: Application
    Filed: November 29, 2010
    Publication date: May 26, 2011
    Applicant: NOVARTIS AG
    Inventors: Peter Wisdom Atadja, Wenlin Shao
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF HODGKIN'S DISEASE
    Publication number: 20110118309
    Abstract: The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of Hodgkins disease.
    Type: Application
    Filed: July 16, 2009
    Publication date: May 19, 2011
    Inventor: Peter Wisdom Atadja
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA
    Publication number: 20110034531
    Abstract: The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2008
    Publication date: February 10, 2011
    Applicant: NOVARTIS AG
    Inventor: Peter Wisdom Atadja
  • Use of HDAC Inhibitors for the Treatment of Bone Destruction
    Publication number: 20100179208
    Abstract: The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis.
    Type: Application
    Filed: May 28, 2008
    Publication date: July 15, 2010
    Applicant: NOVARTIS AG
    Inventors: Peter Wisdom Atadja, Joseph Daniel Growney, Wenlin Shao
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL CANCERS
    Publication number: 20100137398
    Abstract: The present invention relates to the use of an HDAC inhibitor for the preparation of a medicament for the treatment of gastrointestinal cancers; a method of treating a warm-blooded animal, especially a human, having gastrointestinal cancer, comprising administering to said animal a therapeutically effective amount of an HDAC inhibitor, especially a compound of formula (I) as defined herein; and to a pharmaceutical composition and a commercial package.
    Type: Application
    Filed: May 2, 2008
    Publication date: June 3, 2010
    Applicant: NOVARTIS AG
    Inventor: Peter Wisdom Atadja
  • COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER
    Publication number: 20100069458
    Abstract: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
    Type: Application
    Filed: February 13, 2008
    Publication date: March 18, 2010
    Inventors: Peter Wisdom Atadja, Wenlin Shao, Kapil N. Bhalla
  • COMBINATION OF AN HDAC INHIBITOR AND AN ANTIMETABOLITE
    Publication number: 20100069318
    Abstract: The invention relates to a combination which comprises: (a) a HDAI; and (b) an anti-metabolite, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 18, 2010
    Applicant: NOVARTIS AG
    Inventor: Peter Wisdom Atadja
  • USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS
    Publication number: 20090281159
    Abstract: The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of lymphoproliferative diseases, in particular, cutaneous T-cell lymphomas.
    Type: Application
    Filed: June 26, 2007
    Publication date: November 12, 2009
    Applicant: NOVARTIS AG
    Inventors: Peter Wisdom Atadja, Wenlin Shao
  • Combination of Organic Compounds
    Publication number: 20080200489
    Abstract: The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound; and b) an HDAC inhibitor compound, and a method for treating or preventing a proliferative disease using such a combination.
    Type: Application
    Filed: August 10, 2006
    Publication date: August 21, 2008
    Inventors: Peter Wisdom Atadja, Kapil N. Bhalla, Paul W. Manley